Free Trial
NASDAQ:EVGN

Evogene Q3 2023 Earnings Report

Evogene logo
$0.98 -0.02 (-2.06%)
As of 04/17/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Evogene EPS Results

Actual EPS
-$0.80
Consensus EPS
-$1.70
Beat/Miss
Beat by +$0.90
One Year Ago EPS
-$1.60

Evogene Revenue Results

Actual Revenue
$3.77 million
Expected Revenue
$1.09 million
Beat/Miss
Beat by +$2.68 million
YoY Revenue Growth
N/A

Evogene Announcement Details

Quarter
Q3 2023
Time
Before Market Opens
Conference Call Date
Wednesday, November 15, 2023
Conference Call Time
9:00AM ET

Upcoming Earnings

Evogene's Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Thursday, May 22, 2025 at 9:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Conference Call Audio

Earnings Conference Call
Evogene Q3 2023
00:00 / 00:00

Earnings Documents

Evogene Earnings Headlines

Barclays Sticks to Its Buy Rating for Textron (TXT)
Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Textron (TXT) to Release Quarterly Earnings on Thursday
Analysts Set Textron Inc. (NYSE:TXT) PT at $92.09
See More Textron Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Evogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Evogene and other key companies, straight to your email.

About Evogene

Evogene (NASDAQ:EVGN), together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

View Evogene Profile

More Earnings Resources from MarketBeat